Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Tuberculosis

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 13 articles: HTML format

Single Articles

February 2021
1. RAWIZZA HE, Oladokun R, Ejeliogu E, Oguche S, et al
   Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
   J Antimicrob Chemother. 2021;76:710-717.
   PubMed     Abstract available
   
   
   December 2020
2. ALGHAMDI WA, Al-Shaer MH, Kipiani M, Barbakadze K, et al
   Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
   J Antimicrob Chemother. 2020 Dec 30. pii: 6055881. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
   Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
   J Antimicrob Chemother. 2020 Dec 29. pii: 6055076. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. BLACKMAN A, Morrison B, Maruri F, van der Heijden Y, et al
   Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis.
   J Antimicrob Chemother. 2020 Dec 23. pii: 6046147. doi: 10.1093.
   PubMed    
   
   
   
5. TAHSEEN S, vanDeun A, de Jong BC, Decroo T, et al
   Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
   J Antimicrob Chemother. 2020 Dec 1. pii: 6015577. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2020
6. MAITRA A, Evangelopoulos D, Chrzastek A, Martin LT, et al
   Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis.
   J Antimicrob Chemother. 2020 Aug 13. pii: 5892302. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. JACOBS TG, Svensson EM, Musiime V, Rojo P, et al
   Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.
   J Antimicrob Chemother. 2020 Aug 12. pii: 5891804. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2020
8. KADURA S, King N, Nakhoul M, Zhu H, et al
   Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
   J Antimicrob Chemother. 2020 May 3. pii: 5828363. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2020
9. YOSHIDA S, Iwamoto T, Arikawa K, Sekizuka T, et al
   Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient.
   J Antimicrob Chemother. 2020 Apr 17. pii: 5821489. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2020
10. VAN RIE A, Whitfield MG, De Vos E, Scott L, et al
    Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact.
    J Antimicrob Chemother. 2020 Feb 4. pii: 5722231. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2019
11. CHIREHWA MT, McIlleron H, Wiesner L, Affolabi D, et al
    Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    J Antimicrob Chemother. 2019;74:139-148.
    PubMed     Abstract available
    
    
    
12. VON BRAUN A, Castelnuovo B, Ledergerber B, Cusato J, et al
    High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    J Antimicrob Chemother. 2019;74:135-138.
    PubMed     Abstract available
    
    
    March 2018
13. ASHLEY EA, Recht J, Chua A, Dance D, et al
    An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000.
    J Antimicrob Chemother. 2018 Mar 5. pii: 4921008. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: